Cholestatic syndromes

Current Opinion in Gastroenterology

Volumn 17, Issue 3, 2001, Pages 242-256

  Trauner, Michael ^a   Boyer, James L ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; AMOXICILLIN PLUS CLAVULANIC ACID; ANTILIPEMIC AGENT; AZATHIOPRINE; BEZAFIBRATE; BUDESONIDE; CARRIER PROTEIN; COLCHICINE; CORTICOSTEROID; CYCLOSPORIN; ERYTHROMYCIN; ETIDRONIC ACID; FIBRIC ACID DERIVATIVE; FLUORIDE SODIUM; GLUCOCORTICOID; GUAR GUM; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; PREDNISOLONE; PREDNISONE; SILYMARIN; SULINDAC; TACROLIMUS; TAUROURSODEOXYCHOLIC ACID; TETRABAMATE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D RECEPTOR;

BILE SECRETION; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; DRUG INDUCED DISEASE; GENE MUTATION; GENETIC DISORDER; HUMAN; LIVER TRANSPLANTATION; META ANALYSIS; OSTEOPOROSIS; PATHOGENESIS; PREGNANCY DISORDER; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; REVIEW; TOTAL PARENTERAL NUTRITION;

EID: 0035045701     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-200105000-00007     Document Type: Review

References (220)

1. Orphan nuclear receptors: Shifting endocrinology into reverse
2. Transcriptional control of hepatocanalicular transporter gene expression
3. Identification of a nuclear receptor for bile acids
4. Bile acids: Natural ligands for an orphan nuclear receptor
5. Bile acids go nuclear!
6. Bile acids are physiologic ligands for a nuclear receptor
7. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis
8. Don't know much bile-ology
9. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors
10. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
11. Bile acid-mediated feedback inhibition of the NTCP gene promoter occurs via a novel mechanism involving bile acid receptor (FXR) activation of a transcriptional repressor
12. Mechanisms of cholestasis
13. Hepatobiliary transport
14. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders
15. Interleukin-113 suppresses retinoid transactivation of two hepatic transporter genes involved in bile formation
16. Intraabdominal sepsis downregulates transcription of sodium taurocholate cotransporter and multidrug resistance-associated protein in rats
17. Plasma antioxidant levels in chronic cholestatic liver diseases
18. Divergent homeobox gene hex regulates promoter of the Na(+)-dependent bile acid cotransporter
19. Elevated levels of hepatocyte nuclear factor 3beta in mouse hepatocytes influence expression of genes involved in bile acid and glucose homeostasis
20. Structural and functional characterization of liver cell-specific activity of the human sodium/taurocholate cotransporter
21. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases
22. Short-term regulation of canalicular transport
23. Down-regulation by extracellular ATP of rat hepatocyte organic anion transport is mediated by serine phosphorylation of oatp1
24. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (BSEP) of rat liver
25. Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2
26. Mrp2 is essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats
27. Canalicular export pumps traffic with polymeric immunoglobulin A receptor on the same microtubule-associated vesicle in rat liver
28. Bile acid secretion and direct targeting of mdr1-green fluorescent protein from golgi to the canalicular membrane in polarized WIF-B cells
29. Newly synthesized canalicular ABC transporters are directly targeted from the Golgi to the hepatocyte apical domain in rat liver
30. Apical endocytosis in rat hepatocytes In situ involves clathrin, traverses a subapical compartment, and leads to lysosomes
31. Intracellular trafficking and regulation of canalicular ATP-binding cassette transporters
32. Transporters on demand: Intrahepatic pools of canalicular ATP-binding cassette transporters in rat liver
33. Coordinate regulation of the alpha(2)-macroglobulin signaling receptor and the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor by insulin
34. Phosphoinositide 3-kinase lipid products regulate ATP-dependent transport by sister of P-glycoprotein and multidrug resistance associated protein 2 in bile canalicular membrane vesicles
35. Role of the PI3K/PKB signaling pathway in cAMP-mediated translocation of rat liver Ntcp
36. Evidence for apical endocytosis in polarized hepatic cells: Phosphoinositide 3-kinase inhibitors lead to the lysosomal accumulation of resident apical plasma membrane proteins
37. Control by signaling modulators of the sorting of canalicular transporters in rat hepatocyte couplets: Role of the cytoskeleton
38. Cell swelling-indued translocation of rat liver Na+/taurocholate cotransport polypeptide is mediated via the phosphoinositide 3-kinase signaling pathway
39. Effect of cholera toxin and cyclic adenosine monophosphate on fluid-phase endocytosis, distribution, and trafficking of endosomes in rat liver
40. Electron-microscopic demonstration of multidrug resistance protein 2 (Mrp2) retrieval from the canalicular membrane in response to hyperosmolarity and lipopolysaccharide
41. Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver
42. Retrieval of the mrp2 gene encoded conjugate export pump from the canalicular membrane contributes to cholestasis induced by tert-butyl hydroperoxide and chlorodinitrobenzene
43. The rat liver Na+/Bile acid cotransporter (Ntcp): Importance of the cytoplasmic tail to function and plasma membrane targeting
44. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: Evidence for a defect in protein trafficking
45. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome
46. Perfused rat intrahepatic bile ducts secrete and absorb water, solute, and ions
47. Expression of aquaporin-4 water channels in rat cholangiocytes
48. Alternative splicing of the rat sodium/bile acid transporter changes its cellular localization and transport properties
49. Molecular identification and functional characterization of mdr1a in rat cholangiocytes
50. The function of alkaline phosphatase in the liver: Regulation of intrahepatic biliary epithelium secretory activities in the rat
51. Bile acid transport and regulating functions in the human biliary epithelium
52. Regulation and deregulation of cholangiocyte proliferation
53. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats
54. The flavonoid quercetin ameliorates liver damage in rats with biliary obstruction
55. Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity
56. Primary biliary cirrhosis exacerbated by a course of acute hepatitis C and subsequent interferon therapy
57. Bile duct ligation in rats induces biliary expression of cytokine-induced neutrophil chemoattractant
58. Mechanisms of attachment and internalization of cryptosporidium parvum to biliary and intestinal epithelial cells
59. The molecular genetics of familial intrahepatic cholestasis
60. Genetic defects in hepatocanalicular transport
61. A missense mutation in FIC1 is associated with greenland familial cholestasis
62. Ursodeoxycholic acid treatment in children with Byler disease
63. Targeted inactivation of sister of P-glycoprotein gene (spgp) in mice results in non-progressive but persistent intrahepatic cholestasis
64. The bile acid synthetic gene 3beta-hydroxy-Delta(5)-C(27)-steroid oxidoreductase is mutated in progressive intrahepatic cholestasis
65. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease
66. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux
67. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency
68. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1
69. Molecular cloning of the human ATP-binding cassette transporter I (hABC1): Evidence for sterol-dependent regulation in macrophages
70. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers
71. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes
72. Scavenger receptor BI mediates the selective uptake of oxidized cholesterol esters by rat liver
73. Hepatic scavenger receptor BI promotes rapid clearance of high density lipoprotein free cholesterol and its transport into bile
74. The Tangier disease gene encodes yet another pathophysiologically relevant ATP-binding cassette protein
75. Orphans meet cholesterol
76. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters
77. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol
78. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide
79. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family
80. Abnormal hepatic sinusoidal bile acid transport: New insights into the pathogenesis of cholestasis?
81. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis
82. Ursodeoxycholic acid for cystic fibrosis-related liver disease
83. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention
84. JAGGED1 gene expression during human embryogenesis elucidates the wide phenotypic spectrum of Alagille syndrome
85. Apolipoprotein E polymorphism in Alagille syndrome and progressive familial intrahepatic cholestasis
86. Mapping of the locus for cholestasis-lymphedema syndrome (Aagenaes syndrome) to a 6.6-cm interval on chromosome 15q
87. North American Indian cirrhosis in children: A review of 30 cases
88. Liver-directed gene therapy: Promises, problems and prospects at the turn of the century
89. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis
90. Epidemiology and natural history of primary biliary cirrhosis in a US community
91. Smoking and hepato-biliary disease
92. An exploratory population-based case-control study of primary biliary cirrhosis
93. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States
94. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis
95. Fetal microchimerism in primary biliary cirrhosis
96. Detection of male DNA in the liver of female patients with primary biliary cirrhosis
97. PBC: An infectious disease?
98. Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis
99. Identification of Helicobacter pylori and other Helicobacter species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis
100. Helicobacter pylori seroprevalence in hepatitis C virus positive patients with cirrhosis
101. Serum antibodies to Helicobacter hepaticus and Helicobacter pylori in patients with chronic liver disease
102. Detection of Helicobacter pylori DNA in human biliary tree and its association with hepatolithiasis
103. Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis
104. Molecular identification of bacterial 165 ribosomal RNA gene in liver tissue of primary biliary cirrhosis: Is Propionibacterium acnes involved in granuloma formation?
105. Isolation and characterization of a novel virus associated with primary biliary cirrhosis
106. Prevalence of GB virus-C/hepatitis G virus infection in patients with cryptogenic chronic liver disease and in patients with primary biliary cirrhosis or Wilson's disease
107. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis
108. Fine specificity of T cells reactive to human PDC-E2 163-176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: Implications for molecular mimicry and cross-recognition among mitochondrial autoantigens
109. Prediction of the immunodominant epitope of the pyruvate dehydrogenase complex E2 in primary biliary cirrhosis using phage display
110. Mucosal immunity and primary biliary cirrhosis: Presence of antimitochondrial antibodies in urine
111. Apoptosis and liver disease
112. Fas and Fas ligand in gut and liver
113. Mast cell subpopulations in chronic inflammatory hepatobiliary diseases
114. Expression of Bcl-2 familial proteins is reduced in small bile duct lesions of primary biliary cirrhosis
115. Soluble Fas is increased in serum of patients with primary biliary cirrhosis, but is not a useful marker for disease activity
116. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas
117. Multicenter randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis
118. Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibody
119. Fas-mediated cholangiopathy in the murine model of graft versus host disease
120. Mitochondrial membrane perturbations in cholestasis
121. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes
122. The bile acid taurochenodeoxycholate activates a phosphatidylinositol 3-kinase-dependent survival signaling cascade
123. Phosphoinositide 3-kinase-dependent ras activation by tauroursodeoxycholate in rat liver
124. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice
125. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation
126. Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: Evidence for a mitochondrial pathway independent of the permeability transition
127. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease
128. Ursodeoxycholic acid reduces expression of heat shock proteins in primary biliary cirrhosis
129. Impact of fatigue on the quality of life of patients with primary biliary cirrhosis
130. Validation of a fatigue impact score in primary biliary cirrhosis: Towards a standard for clinical and trial use
131. Cholestatic liver diseases and health-related quality of life
132. Primary hepatic lymphoma associated with primary biliary cirrhosis
133. Primary hepatic lymphoma and primary biliary cirrhosis
134. Primary hepatic marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type in a patient with primary biliary cirrhosis
135. Coexistence of primary biliary cirrhosis and myasthenia gravis: A case study
136. Sjogren's syndrome with primary biliary cirrhosis, complicated by transverse myelitis and malignant lymphoma
137. Variant forms of cholestatic diseases involving small bile ducts in adults
138. Autoimmune cholangitis within the spectrum of autoimmune liver disease
139. Ursodeoxycholic acid therapy in hepatobiliary disease
140. Ursodeoxycholic acid for primary biliary cirrhosis: Lessons from the past, issues for the future
141. Management of primary biliary cirrhosis: The American Association for the Study of Liver Diseases practice guidelines
142. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis
143. Ursodeoxycholic acid (UDCA) in primary biliary cirrhosis (PBC): A cochrane hepato-biliary systematic review
144. Ursodeoxycholic acid for primary biliary cirrhosis
145. Ursodeoxycholic acid for primary biliary cirrhosis
146. Bioavailability of four ursodeoxycholic acid preparations
147. Enhancement of ursodeoxycholic acid bioavailability by cross-linked sodium carboxymethyl cellulose
148. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man
149. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial: UDCA-Cooperative Group from the Spanish Association for the Study of the Liver
150. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis
151. Characterization of patients with primary biliary cirrhosis responding to long-term ursodeoxycholic acid treatment
152. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
153. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid
154. A novel treatment for refractory primary biliary cirrhosis?
155. Bezafibrate in the treatment of primary biliary cirrhosis: Comparison with ursodeoxycholic acid
156. Sulindac and ursodeoxycholic acid (UDCA) improve primary biliary cirrhosis (PBC) in patients not responding to UDCA: A prospective controlled pilot study
157. Transplantation for primary biliary cirrhosis: Retrospective analysis of 400 patients in a single center
158. Hepatic osteodystrophy
159. Etidronate for osteoporosis in primary biliary cirrhosis: A randomized trial
160. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis
161. Influence of vitamin D receptor gene polymorphism on bone mineral density in primary biliary cirrhosis
162. Association of primary biliary cirrhosis with vitamin D receptor Bsml genotype polymorphism in a Hungarian population
163. Bone density and metabolism in patients with viral hepatitis and cholestatic liver diseases before and after liver transplantation
164. Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation
165. Collagen type lα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis
166. The interleukin-1 and interleukin-10 gene polymorphisms in primary sclerosing cholangitis: No associations with disease susceptibility/resistance
167. A novel rat model of chronic fibrosing cholangitis induced by local administration of a hapten reagent into the dilated bile duct is associated with increased TNFα production and autoantibodies
168. Progressive development of a Th1-type hepatic cytokine profile in rats with experimental cholangitis
169. Cholestasis with altered structure and function of hepatocyte tight junction and decreased expression of canalicular multispecific organic anion transporter in a rat model of colitis
170. Serum autoantibodies in patients with primary sclerosing cholangitis
171. Clinical significance of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases
172. Overlapping syndrome of autoimmune hepatitis and primary sclerosing cholangitis associated with pyoderma gangrenosum and ulcerative colitis
173. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis
174. Sequential occurrence of primary sclerosing cholangitis and autoimmune hepatitis type III in a patient with ulcerative colitis: A follow-up study over 14 years
175. Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases
176. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: An evaluation of a modified scoring system
177. Increased frequency of autoimmune diseases in patients with primary sclerosing cholangitis
178. Immunological similarities between primary sclerosing cholangitis and chronic sclerosing sialoadenitis: Report of the overlapping of these two autoimmune diseases
179. The role of magnetic resonance cholangiography in primary sclerosing cholangitis
180. Magnetic resonance cholangiography in patients with biliary disease: Its role in primary sclerosing cholangitis
181. Primary sclerosing cholangitis: Evaluation with MR cholangiography: A case-control study
182. Prospective risk assessment of endoscopic retrograde cholangiography in patients with primary sclerosing cholangitis: Dutch PSC Study Group
183. The utility of CA 19-9 in the diagnosis of cholangiocarcinoma in patients without primary sclerosing cholangitis
184. Can DNA cytometry be used or evaluation of malignancy and premalignancy in bile duct strictures in primary sclerosing cholangitis?
185. Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development
186. Medical treatment for primary sclerosing cholangitis: Risk versus benefit
187. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: A randomized double-blind pilot study: Belgian-Dutch PSC Study Group
188. Oral budesonide in the treatment of primary sclerosing cholangitis
189. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis: A case series
190. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis
191. Lack of effect of transdermal nicotine on 3 cases of primary sclerosing cholangitis
192. Intrahepatic cholestasis of pregnancy: Molecular pathogenesis, diagnosis and management
193. Bile acids and progesterone metabolites in intrahepatic cholestasis of pregnancy
194. Differential regulation of hepatic bile salt and organic anion transporters in pregnant end postpartum rats and the role of prolactin
195. Selenium, zinc and copper plasma levels in intrahepatic cholestasis of pregnancy, in normal pregnancies and in healthy individuals, in Chile
196. Effect of maternal cholestasis on bile acid transfer across the rat placenta-maternal liver tandem
197. Ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: A retrospective study of 19 cases
198. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: Effects on primary bile acids in babies and mothers
199. Oral guar gum, a gel-forming dietary fiber relieves pruritus in intrahepatic cholestasis of pregnancy
200. Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure
201. Drug-induced liver diseases
202. Drug and toxin-induced bile duct disorders
203. Clinical diagnostic scale: A useful tool in the evaluation of suspected hepatotoxic adverse drug reactions
204. Comparison of two clinical scales for causality assessment in hepatotoxicity
205. Assessing causality in drug-induced liver injury
206. Co-amoxiclav jaundice: Clinical and histologic features and HLA class II association
207. Ursodeoxycholic acid (UDCA) for the treatment of amoxycillin-clavulanate potassium (Augmentin)-induced intra-hepatic cholestasis: Report of two cases
208. Liver injury due to tetrabamate (Atrium): An analysis of 11 cases
209. Severe cholestasis related to intraconazole for the treatment of onychomycosis
210. Prolonged cholestasis after acute paraquat poisoning through skin absorption
211. Erythromycin-induced primary biliary cirrhosis
212. Symptomatic primary biliary cirrhosis triggered by administration of sulpiride
213. Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration
214. Demonstration of McCune-Albright mutations in the liver of children with high γGT progressive cholestasis
215. Chronic cholestasis associated with Turner's syndrome
216. Hyperbilirubinemia and cholestatic liver injury in hepatitis C-infected liver transplant recipients
217. Vanishing bile duct syndrome associated with chronic EBV infection
218. Churg-Strauss syndrome and granulomatous cholangiopathy
219. Familial idiopathic adulthood ductopenia: A report of five cases in three generations
220. Idiopathic adulthood ductopenia: A diagnosis: Two clinicopathologic courses